Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) in Relapse multiple myeloma: NCT06799026 Clinical Landscape Report 2026
16 October 2026
NCT06799026 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin(ImmunityBio) in Non-Muscle Invasive Bladder Neoplasms: NCT06800963 Clinical Landscape Report 2026
16 October 2026
NCT06800963 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Linperlisib in Multiple Myeloma: NCT06799676 Clinical Landscape Report 2026
16 October 2026
NCT06799676 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) in Multiple Myeloma: NCT06793449 Clinical Landscape Report 2026
16 October 2026
NCT06793449 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine/Cedazuridine in Acute Myeloid Leukemia: NCT06802523 Clinical Landscape Report 2026
16 October 2026
NCT06802523 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in leukemia acute ambiguous lineage: NCT06807606 Clinical Landscape Report 2026
16 October 2026
NCT06807606 clinical landscape for leukemia acute ambiguous lineage: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Autologous adipose derived mesenchymal stem cells (Hope Biosciences) in Multiple Sclerosis, Relapsing-Remitting: NCT06800404 Clinical Landscape Report 2026
16 October 2026
NCT06800404 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Abrocitinib in Eczema: NCT06807281 Clinical Landscape Report 2026
16 October 2026
NCT06807281 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Busulfan in Acute Myeloid Leukemia: NCT06802315 Clinical Landscape Report 2026
16 October 2026
NCT06802315 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Levofloxacin in Acute Myeloid Leukemia: NCT06810583 Clinical Landscape Report 2026
16 October 2026
NCT06810583 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abrocitinib in Eczema: NCT06807268 Clinical Landscape Report 2026
16 October 2026
NCT06807268 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofacitinib Citrate in Dermatitis, Atopic: NCT06810050 Clinical Landscape Report 2026
16 October 2026
NCT06810050 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.